Eupraxia Pharmaceuticals (EPRX) Q2 2026 earnings summary

Executive summary

• Presented new data at Digestive Disease Week showing improvement in fibrosis and inflammation after a single EP-104GI treatment in EoE patients.

• Strengthened executive team and board with key appointments to support late-stage drug development and commercialization.

• Transitioned to a two-hub organization in Vancouver and Seattle, with leadership changes in technical operations and R&D.

Financial highlights

• Reported net loss of $14.5 million for Q2 2026, compared to $8.7 million in Q2 2025, mainly due to increased R&D and administrative costs.

• Cash and cash equivalents of $52.4 million and short-term investments of $81.2 million as of June 30, 2026, up from $80.6 million at the end of Q4 2025.

• Existing cash reserves expected to fund operations into the second half of 2028.

Outlook and guidance

• Interim data from the Phase 2b EoE trial expected in Q4 2026, with Phase 3 trial initiation and expansion of EP-104GI indications planned for 2027.

• Anticipates continued progress in late-stage development and commercialization of EP-104GI.